The Deep Tech Leaders team is delighted to have recently supported DNAe in the appointment of Richard Hammond as their new Vice President of Technology.

Richard has enjoyed a long career developing innovative, first-of-their-kind diagnostics.  For 6-years, he worked at Alere, where he delivered from research a next generation isothermal diagnostic, the world’s first nucleic acid-based diagnostic test to achieve CLIA waiver.  Most recently, Richard has been Technology Director and Head of Bioinnovation at Cambridge Consultants.

About DNAe

The realisation of clinically-applicable, next-generation sequencing solutions represents one of today’s greatest technology challenges.  The potential benefits are enormous, ushering in diagnosis that is faster, more accurate, and far more comprehensive than traditional methods.  But the scale of the challenge is significant.

DNAe is a pioneer in this vital field.  For more than 10-years, the company has applied its expertise in diagnostic and semiconductor technologies to bring innovative, life-saving benefits to patients.  DNAe is taking DNA sequencing from specialised genome centres into hospitals, the clinic and the point of care.

Today, this award-winning company is a highly specialised team of professionals based in London and Carlsbad, California.  The company is developing its DNA sequencing platform for the rapid diagnosis of infectious diseases, antibiotic resistance and cancer.

For more information on DNAe, please refer to their website at dnae.com.

About Deep Tech Leaders

Deep Tech Leaders recruits boards and leadership teams for advanced science & technology businesses aiming to move from the Lab to the Market.  Headquartered in London, we partner with entrepreneurs, executives and investors to build innovative companies across the Industrial, Medical and Advanced Computing domains.